We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Advanced Human Lung Models Developed

Representation of human lungs.
Credit: Kalhh, Pixabay
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

This article is based on research findings that are yet to be peer-reviewed. Results are therefore regarded as preliminary and should be interpreted as such. Find out about the role of the peer review process in researchhere. For further information, please contact the cited source.

Scientists have developed a step-by-step blueprint to create advanced human lung models in the lab, which they say will accelerate the discovery and development of new drugs and reduce reliance on animal testing.

The research due to be published in Biomaterials Research is available online as a preprint, led by the University of Sydney’s Dr Huyen Phan with collaborators from Australia, South Korea and China.

Lab-made lungs, known as organoids or mini-organs, are 3D structures grown from human primary cells that mirror real organs in the body. They serve as a testing ground for biomedical research.

Senior author Professor Wojciech Chrzanowski, Professor of Nanomedicine in the Sydney Pharmacy School, Faculty of Medicine, and member of the Charles Perkins Centre, said: “This work is significant because we will be able to reduce the number of animals in medical research and accelerate the discovery of new drugs or innovative strategies to treat diseases.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

“We decided to build two different lung models, one of which mimics phase one clinical trials; a healthy lung to study safety of new drugs. The other one mimics phase two trials; a diseased lung that, in our case, mirrors chronic obstructive pulmonary disease, enabling us to study the therapeutic effectiveness or superiority of the drugs.

“We take cells directly from patients and then build them in layers as they exist inside the body. So, first you have the epithelial cells, then you have the fibroblasts – we are literally creating a mimic organ that is very much like actual human lungs.”

Professor Chrzanowski said the models described in the paper, which are more accurate than traditional models, are unique for their ability to emulate the environmental conditions of a human lung. Similar models are now being used by AstraZeneca and the US Food and Drug Administration.

“With a traditional cell culture, you put cells into a Petri dish and culture them in static conditions, which is far from what happens in a human body. What we are doing is creating environmental conditions similar to those which exist in the human body,” Dr Phan said.

“We culture and maintain our models under the micro-environmental conditions of lungs, with air on one side and liquid interface at the bottom, combined with microcirculation, which is our circulatory system or blood.”

“These two elements combined help emulate the conditions of a human lung, making them more accurate.”

Uses for the lung models aren’t isolated to drug discovery. They can also be personalized to individual patients and be used to test a range of reactions in the lung.

“These mini-lung organoid models can also be used to test toxicity. For example, of silica dust or air pollutants, such as particulates generated during bush fires,” Professor Chrzanowski said.

“Because we can take cells directly from individual patients, we can build a patient’s own model to test the effectiveness of drugs on them.”

Professor Chrzanowski said the lung models could have a major impact on basic science, enabling the discovery of how different organs function and how to design the most effective therapeutic strategies.

The researchers said the huge advantage of their models are their reproducibility, reliability and the ability to conduct research in a cost-effective way at a large scale.

“They accelerate the process of discovery, they shorten the process of getting to clinics, but also substantially increase our confidence in the molecules we create before we go to clinical trials,” Professor Chrzanowski said. 

“The normal timeline for the clinical translation of a drug is about 10 to 15 years, but when you use organoid models, you can shrink that time substantially.”

Development of these lung models brings Australia to the forefront of mini organ research, said Professor Chrzanowski, who has been calling for the establishment of a national center for medical research alternatives to animal methods.

Australia banned cosmetic testing on animals in 2020, and last year the United States passed legislation ending a requirement for new drugs to be tested on animals.

Reference: Phan TH, Shi H, Denes CE, et al. Advanced pathophysiology mimicking lung models for accelerated drug discovery. 2023. PREPRINT available at Research Square. doi: 10.21203/rs.3.rs-2473300/v1

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.